4.7 Article

Novel Biochemical Markers of Glycemia to Predict Pregnancy Outcomes in Women With Type 1 Diabetes

Journal

DIABETES CARE
Volume 44, Issue 3, Pages 681-689

Publisher

AMER DIABETES ASSOC
DOI: 10.2337/dc20-2360

Keywords

-

Funding

  1. JDRF [17-2011-533, 80-2010-585]
  2. FedDev Ontario
  3. European Foundation for the Study of Diabetes (EFSD)/Sanofi Pilot Research Grants for Innovative Measurement of Diabetes Outcomes, 2017
  4. Diabetes UK [DUK-HKF 17/0005712]
  5. EFSD-Novo Nordisk Foundation Future Leaders Award [NNF19SA058974]
  6. National Institute for Health Research [CDF-2013-06-035]
  7. Tommy's charity

Ask authors/readers for more resources

This study found that HbA(1c), CGM metrics, and alternative biochemical markers were all predictive of obstetric and neonatal outcomes in pregnant women with type 1 diabetes. CGM metrics were more associated with outcomes in the first trimester, while laboratory markers were more associated with outcomes in the third trimester. Time in range (TIR) and time above range (TAR) were the most consistently predictive CGM metrics, and HbA(1c) was also a consistent predictor of suboptimal pregnancy outcomes.
OBJECTIVE The optimal method of monitoring glycemia in pregnant women with type 1 diabetes remains controversial. This study aimed to assess the predictive performance of HbA(1c), continuous glucose monitoring (CGM) metrics, and alternative biochemical markers of glycemia to predict obstetric and neonatal outcomes. RESEARCH DESIGN AND METHODS One hundred fifty-seven women from the Continuous Glucose Monitoring in Women With Type 1 Diabetes in Pregnancy Trial (CONCEPTT) were included in this prespecified secondary analysis. HbA(1c), CGM data, and alternative biochemical markers (glycated CD59, 1,5-anhydroglucitol, fructosamine, glycated albumin) were compared at similar to 12, 24, and 34 weeks' gestation using logistic regression and receiver operating characteristic (ROC) curves to predict pregnancy complications (preeclampsia, preterm delivery, large for gestational age, neonatal hypoglycemia, admission to neonatal intensive care unit). RESULTS HbA(1c), CGM metrics, and alternative laboratory markers were all significantly associated with obstetric and neonatal outcomes at 24 weeks' gestation. More outcomes were associated with CGM metrics during the first trimester and with laboratory markers (area under the ROC curve generally <0.7) during the third trimester. Time in range (TIR) (63-140 mg/dL [3.5-7.8 mmol/L]) and time above range (TAR) (>140 mg/dL [>7.8 mmol/L]) were the most consistently predictive CGM metrics. HbA(1c) was also a consistent predictor of suboptimal pregnancy outcomes. Some alternative laboratory markers showed promise, but overall, they had lower predictive ability than HbA(1c). CONCLUSIONS HbA(1c) is still an important biomarker for obstetric and neonatal outcomes in type 1 diabetes pregnancy. Alternative biochemical markers of glycemia and other CGM metrics did not substantially increase the prediction of pregnancy outcomes compared with widely available HbA(1c) and increasingly available CGM metrics (TIR and TAR).

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available